· Intro
· PC
· PK
· PD
· Used as a sole agent in 3rd world and field anaesthesia
· Anaesthetic: for induction (bolus) and maintenance (infusion or repeat boluses)
· Analgesic
· Relatively safe cardiovascular and respiratory profile
· Cheap
· Stable in solution
· No toxic additives (benzethonium chloride: theoretical risk neurotoxicity)
· Low risk of bacterial growth
· No bacterial growth
· No histamine release
· No anaphylaxis
· No pain on IV injection
· Suitable for IM injection of IV access lost
Administration |
· Many routes: IV, IM, SC, intranasal, PO · Used for oral premedication in children · For IM sedation of patients without IV access |
Time course |
· Fast onset (30 seconds) · Fast peak (90 seconds) · Duration highly dependent upon dose |
Absorption |
N/A |
Distribution |
· Very high lipid solubility (5-10x that of thiopentone) · Very fast effect site equilibration (t1/2ke0 0.5 minutes) o Suitable for induction · Large VDSS 3L/kg · Rapid distribution o Can be rapid offset after a bolus |
Metabolism |
· Hepatic, phase 1, CYP3A4 N-demethylation > other · High hepatic extraction ratio, flow-dependent clearance · Subject to induction and inhibition · Active metabolite norketamine (30% as active) o May increase duration of effect o Inactivated by hydroxylation then conjugation o t1/2β 4 hours · Rapid clearance 17mL/kg/min and short t1/2β 2 hours o Suitable for maintenance infusion · Can be hepatotoxic |
Excretion |
· Active metabolite renally excreted; accumulates in renal failure |
Mechanisms |
· Principal: non-competitive NMDA antagonist at PCP site · Other ↑: 2PK/5HT3/mu opioid · Other ↓: VDNaC, VdCC, monoamine reuptake, nnAChR |
Anaesthesia |
· Thalamocortical dissocation (amnesia, sedation, hypnosis, immobility; not anxiolytic) · Atypical effect on EEG; not suitable for BIS or entropy monitoring · S-ketamine more potent than R-ketamine |
Other beneficial effects |
· Analgesia: o Multiple mechanisms (↓NMDA, ↑monoamines, ↑↓opioids, VDNaC) o ↓Acute and chronic pain o ↓Somatic and neuropathic o ↓Hyperalgaesia and allodynia o Opioid-sparing · Anaesthesia + analgesia allows use as a sole agent (e.g. field anaesthesia, 3rd world) |
Side effects |
· Emergence delirium: o R-ketamine > S-ketamine o Hallucinations, nightmares in 30% o Higher risk if psychiatric illness o ?Attenuated by midazolam · Emetogenic · ↑CMRO2, ↑CBF +/- ↑ICP o Contraindicated if CNS bleed or tumour with ↑ICP |
Unclear effects |
· Both pro- and anti-convulsant · Neurotoxic to the developing brain; but may attenuate excitotoxicity in HIBI |
Direct effects |
· R-ketamine > S-ketamine · Negative inotropy, venodilatation, vasodilatation |
Indirect effect |
· ↑SNS output from medulla o ↑HR, ↑contractility, ↑SVR o ↑MVO2 -> risk myocardial ischaemia o ↑PVR -> ↑RV strain (avoid ↓PaO2, ↑PaCO2) · Direct effects balance indirect effects in health · Negative inotropy may be unmasked if maximal SNS activity or high dose vasoactives · Baroreceptor reflex relatively preserved |
|
· Thalamocortical dissociation with relative preservation of vital medullary activity · ↑SNS output and ↓L-Ca2+ -> smooth muscle relaxation |
Beneficial effects |
· Preserved ventilation (↔RR, TV), airway reflexes and pharyngeal dilator tone · Preserved airway reflexes · Preserved pharyngeal dilator tone · R-ketamine-> bronchodilation (suitable induction agent in status asthmaticus) · Ideal for field anaesthesia or if limited resources · May be inadequate alone for airway instrumentation |
Side effects |
· ↑Airway secretion (may need anti-sialogogue) |
Feedback welcome at ketaminenightmares@gmail.com